Fergus J Couch

List of Publications by Year in Descending Order

387 papers	30,991 citations	86 h-index	167 g-index
406 ext. papers	37,104 ext. citations	9.3 avg, IF	6.04 L-index

#	Paper	IF	Citations
387	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
386	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3
385	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.. *Nature Communications*, **2022**, 13, 514	17.4	2
384	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. *JAMA Oncology*, **2022**,	13.4	5
383	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.. *EMBO Molecular Medicine*, **2022**, e14552	12	2
382	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFB/p65 signaling in triple negative breast cancer.. *Npj Breast Cancer*, **2022**, 8, 20	7.8	0
381	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.. *Breast Cancer Research*, **2022**, 24, 27	8.3	1
380	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women.. *Scientific Reports*, **2022**, 12, 6199	4.9	
379	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. *Journal of the National Cancer Institute*, **2021**, 113, 1105-1108	9.7	3
378	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. *Genetics in Medicine*, **2021**,	8.1	2
377	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Scientific Reports*, **2021**, 11, 19787	4.9	0
376	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. *Journal of Clinical Oncology*, **2021**, 39, 3918-3926	2.2	6
375	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. *BMJ Open*, **2021**, 11, e053397	3	1
374	Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 1429-1433	9.7	5
373	Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study. *Cancers*, **2021**, 13,	6.6	6
372	Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. *American Journal of Human Genetics*, **2021**, 108, 458-468	11	12
371	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. *European Journal of Cancer*, **2021**, 145, 44-52	7.5	2

370	Germline pathogenic variants in cancer predisposition genes among women with invasive lobular cancer of breast.. *Journal of Clinical Oncology*, **2021**, 39, 10581-10581	2.2	
369	Closing the gap: Trends in inconclusive rates on hereditary cancer testing across racial/ethnic groups.. *Journal of Clinical Oncology*, **2021**, 39, 10525-10525	2.2	1
368	Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs).. *Journal of Clinical Oncology*, **2021**, 39, 548-548	2.2	
367	Mutations in and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. *Journal of Clinical Oncology*, **2021**, 39, 1619-1630	2.2	11
366	Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.. *Journal of Clinical Oncology*, **2021**, 39, 10500-10500	2.2	
365	First international workshop of the ATM and cancer risk group (4-5 December 2019). *Familial Cancer* , **2021**, 1	3	5
364	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
363	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 5628-5637	12.9	8
362	PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. *Gynecologic Oncology*, **2021**, 162, 182-189	4.9	2
361	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
360	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. *Journal of Clinical Oncology*, **2021**, 39, 3430-3440	2.2	3
359	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. *Breast Cancer Research and Treatment*, **2021**, 189, 15-23	4.4	2
358	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *Journal of the National Cancer Institute*, **2021**, 113, 329-337	9.7	14
357	Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years. *Cancer*, **2021**, 127, 828-833	6.4	6
356	Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. *Cancer Prevention Research*, **2021**, 14, 175-184	3.2	3
355	Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer. *Human Mutation*, **2021**, 42, 290-299	4.7	9
354	Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. *Genetics in Medicine*, **2021**, 23, 306-315	8.1	5
353	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 557-566	4.4	5

352	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *British Journal of Cancer*, **2021**, 124, 842-854	8.7	2
351	Real-World Experiences With Yoga on Cancer-Related Symptoms in Women With Breast Cancer. *Global Advances in Health and Medicine*, **2021**, 10, 2164956120984140	1.9	4
350	Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes. *Breast Cancer Research and Treatment*, **2021**, 187, 215-224	4.4	3
349	A Population-Based Study of Genes Previously Implicated in Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 440-451	59.2	115
348	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. *European Journal of Cancer*, **2021**, 152, 68-77	7.5	5
347	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
346	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. *JAMA Oncology*, **2021**, 7, 1045-1050	13.4	7
345	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86	8.3	1
344	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. *Journal of Clinical Oncology*, **2021**, 39, 2564-2573	2.2	12
343	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
342	Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*, **2021**, 596, 393-397	50.4	28
341	Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer. *Npj Breast Cancer*, **2021**, 7, 130	7.8	0
340	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 623-642	4	4
339	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. *PLoS ONE*, **2021**, 16, e0245664	3.7	1
338	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
337	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. *Journal of the National Cancer Institute*, **2020**, 112, 1213-1221	9.7	25
336	Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML. *Npj Breast Cancer*, **2020**, 6, 13	7.8	5
335	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2

334	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. *Journal of Medical Genetics*, **2020**, 57, 509-518	5.8	14
333	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. *Journal of Clinical Oncology*, **2020**, 38, 1409-1418	2.2	28
332	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
331	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. *Npj Breast Cancer*, **2020**, 6, 4	7.8	19
330	The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. *Journal of the National Cancer Institute*, **2020**, 112, 1231-1241	9.7	25
329	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51
328	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
327	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 599-605	4	4
326	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nature Communications*, **2020**, 11, 312	17.4	20
325	Reply to On the proportion of male breast cancer among all breast cancers. *Cancer*, **2020**, 126, 2034-2035	5.4	1
324	Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry. *JCO Precision Oncology*, **2020**, 4, 32-43	3.6	13
323	Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study. *Supportive Care in Cancer*, **2020**, 28, 5833-5838	3.9	3
322	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
321	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. *Journal of Clinical Oncology*, **2020**, 38, 1087-1087	2.2	2
320	Uptake of oophorectomy in women with findings on multigene panel testing: Results from the Prospective Registry of Multiplex Testing (PROMPT).. *Journal of Clinical Oncology*, **2020**, 38, 1508-1508	2.2	3
319	N-terminal pro-brain natriuretic peptide levels after receipt of anthracycline for breast cancer.. *Journal of Clinical Oncology*, **2020**, 38, e24103-e24103	2.2	
318	Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.. *Journal of Clinical Oncology*, **2020**, 38, 510-510	2.2	0
317	Genetic testing experiences and emotional reactions among individuals with variant of uncertain significance results from cancer multiplex genetic testing.. *Journal of Clinical Oncology*, **2020**, 38, e13680-e13680	2.2	

316	Functional characterization of 84 PALB2 variants of uncertain significance. *Genetics in Medicine*, **2020**, 22, 622-632	8.1	20
315	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
314	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
313	Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. *Genetics in Medicine*, **2020**, 22, 701-708	8.1	18
312	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2020**, 26, 6505-6512	12.9	15
311	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. *Gynecologic Oncology*, **2020**, 159, 820-826	4.9	3
310	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
309	A Rare Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. *Cancer Research*, **2020**, 80, 3732-3744	10.1	7
308	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
307	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
306	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. *Cancer*, **2020**, 126, 26-36	6.4	33
305	A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. *Genetics in Medicine*, **2020**, 22, 407-415	8.1	68
304	Mutation prevalence tables for hereditary cancer derived from multigene panel testing. *Human Mutation*, **2020**, 41, e1-e6	4.7	10
303	Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening. *BioTechniques*, **2019**, 67, 118-122	2.5	6
302	Accuracy of self-reported cancer treatment data in young breast cancer survivors. *Journal of Patient-Reported Outcomes*, **2019**, 3, 24	2.6	3
301	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
300	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
299	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. *Breast Cancer Research*, **2019**, 21, 68	8.3	18

298	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52
297	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
296	Hereditary Cancer Syndromes-A Primer on Diagnosis and Management, Part 2: Gastrointestinal Cancer Syndromes. *Mayo Clinic Proceedings*, **2019**, 94, 1099-1116	6.4	18
295	Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. *Mayo Clinic Proceedings*, **2019**, 94, 1084-1098	6.4	22
294	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Human Mutation*, **2019**, 40, 1781-1796	4.7	16
293	Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, 61-74	7.1	26
292	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
291	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
290	Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. *Journal of Biological Chemistry*, **2019**, 294, 5980-5992	5.4	19
289	Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. *Genetics in Medicine*, **2019**, 21, 71-80	8.1	36
288	Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. *Journal of Immigrant and Minority Health*, **2019**, 21, 434-437	2.2	8
287	Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. *Journal of the National Cancer Institute*, **2019**, 111, 264-271	9.7	5
286	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. *Fertility and Sterility*, **2019**, 112, 731-739.e1	4.8	5
285	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
284	Leptomeningeal carcinomatosis in BRCA-mutated pancreatic cancer.. *Journal of Clinical Oncology*, **2019**, 37, 239-239	2.2	1
283	Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. *JCO Precision Oncology*, **2019**, 3,	3.6	5
282	Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Medicine*, **2019**, 12, 3	14.4	106
281	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2019**, 175, 443-449	4.4	7

280	Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. *Nature Communications*, **2019**, 10, 5296	17.4	21
279	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
278	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. *Blood*, **2019**, 133, 1130-1139	2.2	17
277	Cancer susceptibility gene mutations in type I and II endometrial cancer. *Gynecologic Oncology*, **2019**, 152, 20-25	4.9	19
276	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. *Breast Cancer Research and Treatment*, **2019**, 173, 667-677	4.4	16
275	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
274	Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. *Genetics in Medicine*, **2019**, 21, 1497-1506	8.1	32
273	The BRCA2 c.68-7T▯▯A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Human Mutation*, **2018**, 39, 729-741	4.7	16
272	Clinical testing of and : a worldwide snapshot of technological practices. *Npj Genomic Medicine*, **2018**, 3, 7	6.2	29
271	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2018**, 110, 1030-1034	9.7	65
270	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. *International Journal of Cancer*, **2018**, 143, 746-757	7.5	9
269	Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. *Breast Cancer Research and Treatment*, **2018**, 170, 129-141	4.4	7
268	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. *Current Treatment Options in Cardiovascular Medicine*, **2018**, 20, 18	2.1	4
267	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. *Cancer Medicine*, **2018**, 7, 1978-1987	4.8	40
266	Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. *American Journal of Human Genetics*, **2018**, 102, 233-248	11	38
265	Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 380-394	4	65
264	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. *International Journal of Epidemiology*, **2018**, 47, 526-536	7.8	53
263	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. *Scientific Reports*, **2018**, 8, 6574	4.9	19

262	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. *Journal of Medical Genetics*, **2018**, 55, 15-20	5.8	36
261	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2018**, 167, 89-99	4.4	48
260	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. *Journal of the National Cancer Institute*, **2018**, 110, 855-862	9.7	145
259	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
258	Identification of nine new susceptibility loci for endometrial cancer. *Nature Communications*, **2018**, 9, 3166	17.4	70
257	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
256	Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. *JAMA - Journal of the American Medical Association*, **2018**, 319, 2401-2409	27.4	222
255	Polygenic risk score for breast cancer in high-risk women.. *Journal of Clinical Oncology*, **2018**, 36, 1508-1508	2.2	8
254	Prospective Registry of Multiplex Testing (PROMPT): Feasible and sustainable.. *Journal of Clinical Oncology*, **2018**, 36, 1543-1543	2.2	2
253	Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.. *Journal of Clinical Oncology*, **2018**, 36, 536-536	2.2	19
252	Inherited mutations in breast cancer patients with and without multiple primary cancers.. *Journal of Clinical Oncology*, **2018**, 36, 1503-1503	2.2	
251	Expanding BRCA1/2 testing criteria to include other confirmed breast and ovarian cancer susceptibility genes.. *Journal of Clinical Oncology*, **2018**, 36, 1524-1524	2.2	
250	Examining patients medical and psychosocial experiences following detection of a CDH1 variant with multiplex genetic testing.. *Journal of Clinical Oncology*, **2018**, 36, 1583-1583	2.2	
249	Accuracy of self-reported chemotherapy regimens in young breast cancer survivors.. *Journal of Clinical Oncology*, **2018**, 36, e22143-e22143	2.2	
248	Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. *Pancreatology*, **2018**, 18, 46-53	3.8	6
247	From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. *Journal of Community Genetics*, **2018**, 9, 209-215	2.5	5
246	BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. *Journal of Clinical Oncology*, **2018**, 36, 2281-2287	2.2	56
245	Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes. *JCO Precision Oncology*, **2018**, 2,	3.6	16

244	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genetics*, **2018**, 14, e1007752	6	90
243	A contemporary review of male breast cancer: current evidence and unanswered questions. *Cancer and Metastasis Reviews*, **2018**, 37, 599-614	9.6	32
242	Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. *Breast Cancer Research and Treatment*, **2017**, 161, 575-586	4.4	81
241	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. *European Journal of Human Genetics*, **2017**, 25, 432-438	5.3	15
240	Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. *Cancer Research*, **2017**, 77, 2789-2799	10.1	49
239	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nature Genetics*, **2017**, 49, 834-841	36.3	257
238	Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. *JAMA Oncology*, **2017**, 3, 1190-1196	13.4	349
237	Non-BRCA familial breast cancer: review of reported pathology and molecular findings. *Pathology*, **2017**, 49, 363-370	1.6	17
236	Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes. *Breast Cancer Research and Treatment*, **2017**, 165, 421-431	4.4	9
235	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *Npj Breast Cancer*, **2017**, 3, 22	7.8	78
234	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
233	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
232	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
231	Alcohol consumption and breast tumor gene expression. *Breast Cancer Research*, **2017**, 19, 108	8.3	18
230	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. *Breast Cancer Research*, **2017**, 19, 119	8.3	26
229	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
228	Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. *Gynecologic Oncology*, **2017**, 147, 375-380	4.9	70
227	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. *International Journal of Cancer*, **2017**, 141, 1830-1840	7.5	13

226	Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. *Annals of Surgical Oncology*, **2017**, 24, 3067-3072	3.1	40
225	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. *Nature Communications*, **2017**, 8, 1632	17.4	13
224	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
223	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genetics in Medicine*, **2017**, 19, 599-603	8.1	51
222	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
221	Body mass index and breast cancer survival: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2017**, 46, 1814-1822	7.8	27
220	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	10
219	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. *Oncotarget*, **2017**, 8, 18381-18398	3.3	7
218	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
217	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
216	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Human Molecular Genetics*, **2016**, 25, 3863-3876	5.6	24
215	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1503-1510	4	42
214	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. *Scientific Reports*, **2016**, 6, 36874	4.9	2
213	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
212	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
211	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
210	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
209	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). *Scientific Reports*, **2016**, 6, 32512	4.9	16

208	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. *Breast Cancer Research*, **2016**, 18, 104	8.3	44
207	The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk. *Breast Cancer Research*, **2016**, 18, 111	8.3	9
206	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *Journal of Clinical Oncology*, **2016**, 34, 2750-60	2.2	107
205	Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nature Reviews Clinical Oncology*, **2016**, 13, 581-8	19.4	200
204	Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. *Annals of Surgical Oncology*, **2016**, 23, 3232-8	3.1	34
203	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. *Endocrine-Related Cancer*, **2016**, 23, 77-91	5.7	41
202	Genomic Biomarkers for Breast Cancer Risk. *Advances in Experimental Medicine and Biology*, **2016**, 882, 1-32	3.6	26
201	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Human Molecular Genetics*, **2016**, 25, 2256-2268	5.6	55
200	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *Journal of Medical Genetics*, **2016**, 53, 298-309	5.8	83
199	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
198	Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. *Cancer Research*, **2016**, 76, 749-61	10.1	23
197	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. *British Journal of Cancer*, **2016**, 114, 298-304	8.7	5
196	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
195	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
194	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 207-11	4	88
193	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
192	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
191	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Medicine*, **2016**, 13, e1002105	11.6	80

190	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
189	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS ONE*, **2016**, 11, e0160316	3.7	11
188	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26
187	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
186	Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. *Npj Genomic Medicine*, **2016**, 1,	6.2	55
185	Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. *Breast Cancer Research*, **2016**, 18, 98	8.3	26
184	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
183	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. *Breast Cancer Research and Treatment*, **2016**, 157, 117-31	4.4	17
182	Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Research*, **2016**, 18, 22	8.3	31
181	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes and Control*, **2016**, 27, 679-93	2.8	15
180	Five endometrial cancer risk loci identified through genome-wide association analysis. *Nature Genetics*, **2016**, 48, 667-674	36.3	56
179	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American Journal of Human Genetics*, **2016**, 98, 801-817	11	86
178	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
177	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. *Journal of Clinical Oncology*, **2016**, 34, 4071-4078	2.2	110
176	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discovery* , **2016**, 6, 1267-1275	24.4	30
175	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *American Journal of Human Genetics*, **2016**, 99, 903-911	11	43
174	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
173	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406

172	The contributions of breast density and common genetic variation to breast cancer risk. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	128
171	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55	5.6	68
170	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *American Journal of Human Genetics*, **2015**, 97, 22-34	11	26
169	Identification of novel genetic markers of breast cancer survival. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	38
168	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
167	Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristics. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 798-809	4	38
166	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. *Cancer Research*, **2015**, 75, 2457-67	10.1	45
165	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
164	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Medicine*, **2015**, 13, 156	11.4	37
163	The association of copy number variation and percent mammographic density. *BMC Research Notes*, **2015**, 8, 297	2.3	1
162	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	74
161	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. *Endocrine-Related Cancer*, **2015**, 22, 851-61	5.7	19
160	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1680-91	4	17
159	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
158	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Human Molecular Genetics*, **2015**, 24, 1478-92	5.6	46
157	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
156	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. *Scientific Reports*, **2015**, 5, 17369	4.9	27
155	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. *BMC Cancer*, **2015**, 15, 978	4.8	6

154	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
153	Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Research*, **2015**, 17, 58	8.3	24
152	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. *Breast Cancer Research*, **2015**, 17, 110	8.3	13
151	Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. *Frontiers in Oncology*, **2015**, 5, 191	5.3	11
150	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
149	Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma. *BioMed Research International*, **2015**, 2015, 593572	3	20
148	SNP-SNP interaction analysis of NF-B signaling pathway on breast cancer survival. *Oncotarget*, **2015**, 6, 37979-94	3.3	19
147	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
146	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
145	Gene-panel sequencing and the prediction of breast-cancer risk. *New England Journal of Medicine*, **2015**, 372, 2243-57	59.2	587
144	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. *EBioMedicine*, **2015**, 2, 681-9	8.8	44
143	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 304-11	2.2	435
142	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84	5.6	36
141	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. *Journal of Medical Genetics*, **2015**, 52, 224-30	5.8	28
140	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics*, **2015**, 96, 5-20	11	59
139	A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. *Genetics in Medicine*, **2015**, 17, 739-46	8.1	20
138	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. *Oncotarget*, **2015**, 6, 7390-407	3.3	14
137	Functional assays for analysis of variants of uncertain significance in BRCA2. *Human Mutation*, **2014**, 35, 151-64	4.7	75

136	Two decades after BRCA: setting paradigms in personalized cancer care and prevention. *Science*, **2014**, 343, 1466-70	33.3	233
135	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genetic Epidemiology*, **2014**, 38, 84-93	2.6	24
134	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. *Carcinogenesis*, **2014**, 35, 1012-9	4.6	121
133	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. *Nature Communications*, **2014**, 5, 5303	17.4	84
132	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 15172-7	11.5	128
131	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature*, **2014**, 514, 92-97	50.4	401
130	Breast-cancer risk in families with mutations in PALB2. *New England Journal of Medicine*, **2014**, 371, 497-506	59.2	576
129	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications*, **2014**, 4, 4999	17.4	87
128	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46	5.6	11
127	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. *Human Pathology*, **2014**, 45, 1630-8	3.7	179
126	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Research*, **2014**, 16, R51	8.3	12
125	A genome wide meta-analysis study for identification of common variation associated with breast cancer prognosis. *PLoS ONE*, **2014**, 9, e101488	3.7	24
124	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
123	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genetics*, **2014**, 10, e1004285	6	38
122	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
121	The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. *Cell Reports*, **2014**, 9, 1318-32	10.6	15
120	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
119	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46

118	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium **2014**, n/a-n/a		1
117	A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. *Cancer Research*, **2013**, 73, 265-75	10.1	77
116	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *American Journal of Human Genetics*, **2013**, 93, 1046-60	11	80
115	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
114	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American Journal of Human Genetics*, **2013**, 92, 489-503	11	167
113	Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. *Gastroenterology*, **2013**, 145, 1098-1109.e1	13.3	126
112	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2	36.3	327
111	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, **2013**, 45, 353-61, 361e1-2	36.3	813
110	A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. *Breast Cancer Research and Treatment*, **2013**, 138, 529-542	4.4	14
109	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. *Endocrine-Related Cancer*, **2013**, 20, 875-87	5.7	19
108	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
107	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
106	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genetics*, **2013**, 9, e1003284	6	112
105	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. *Cancer Discovery* , **2013**, 3, 399-405	24.4	106
104	BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. *Oncologist*, **2013**, 18, 518-24	5.7	61
103	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
102	SoftSearch: integration of multiple sequence features to identify breakpoints of structural variations. *PLoS ONE*, **2013**, 8, e83356	3.7	30
101	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70

100	A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). *Human Mutation*, **2012**, 33, 8-21	4.7	143
99	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. *Human Mutation*, **2012**, 33, 2-7	4.7	211
98	Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. *Human Mutation*, **2012**, 33, 22-8	4.7	56
97	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
96	The influence of mammogram acquisition on the mammographic density and breast cancer association in the Mayo Mammography Health Study cohort. *Breast Cancer Research*, **2012**, 14, R147	8.3	39
95	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
94	Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nature Genetics*, **2012**, 44, 312-8	36.3	237
93	Mutation screening of RAD51C in high-risk breast and ovarian cancer families. *Familial Cancer*, **2012** , 11, 381-5	3	17
92	BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. *Developmental Cell*, **2012**, 23, 137-52	10.2	65
91	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. *Human Molecular Genetics*, **2012**, 21, 5373-84	5.6	143
90	11q13 is a susceptibility locus for hormone receptor positive breast cancer. *Human Mutation*, **2012**, 33, 1123-32	4.7	33
89	A guide for functional analysis of BRCA1 variants of uncertain significance. *Human Mutation*, **2012**, 33, 1526-37	4.7	94
88	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
87	Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1156-66	4	92
86	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. *Journal of Medical Genetics*, **2012**, 49, 525-32	5.8	82
85	Identification of a novel percent mammographic density locus at 12q24. *Human Molecular Genetics*, **2012**, 21, 3299-305	5.6	28
84	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. *Cancer Research*, **2012**, 72, 1795-803	10.1	93
83	Mammographic breast density and breast cancer: evidence of a shared genetic basis. *Cancer Research*, **2012**, 72, 1478-84	10.1	50

82	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
81	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
80	CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 4308-16	2.2	134
79	The role of genetic breast cancer susceptibility variants as prognostic factors. *Human Molecular Genetics*, **2012**, 21, 3926-39	5.6	75
78	Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. *Gastroenterology*, **2011**, 140, 1303-1313.e1-3	13.3	56
77	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. *Cancer Research*, **2011**, 71, 5792-805	10.1	44
76	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
75	Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. *Nature Genetics*, **2011**, 43, 185-7	36.3	96
74	Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 617-22	4.4	21
73	Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. *Human Mutation*, **2011**, 32, 678-87	4.7	39
72	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2222-31	4	27
71	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of the National Cancer Institute*, **2011**, 103, 250-63	9.7	513
70	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011** , 20, 3289-303	5.6	140
69	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nature Genetics*, **2011**, 43, 1210-4	36.3	253
68	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
67	Assessment of hepatocyte growth factor in ovarian cancer mortality. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1638-48	4	30
66	A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1078-88	4	42
65	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. *Cancer Research*, **2011**, 71, 6240-9	10.1	100

64	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
63	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
62	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
61	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2010**, 19, 2886-97	5.6	56
60	Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 251-7	4	20
59	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA - Journal of the American Medical Association*, **2010**, 304, 967-75	27.4	993
58	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32
57	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
56	Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. *Journal of the National Cancer Institute*, **2010**, 102, 650-62	9.7	45
55	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2010**, 12, R102	8.3	21
54	Association of genetic variation in mitotic kinases with breast cancer risk. *Breast Cancer Research and Treatment*, **2010**, 119, 453-62	4.4	21
53	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. *Familial Cancer*, **2010**, 9, 495-502	3	39
52	Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. *Human Mutation*, **2010**, 31, E1484-503	4.7	48
51	Association of breast cancer susceptibility variants with risk of pancreatic cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 3044-8	4	20
50	Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1864-8	4	26
49	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
48	Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2549-52	4	8
47	Genome-wide association studies identify new breast cancer susceptibility genes. *Current Breast Cancer Reports*, **2009**, 1, 131-138	0.8	3

46	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*, **2009**, 41, 585-90	36.3	393
45	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature*, **2008**, 451, 1116-20	50.4	757
44	Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. *Breast Cancer Research*, **2008**, 10, R98	8.3	36
43	Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2101-8	4	60
42	Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. *Journal of Clinical Oncology*, **2008**, 26, 5393-400	2.2	74
41	Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. *Cancer Research*, **2008**, 68, 971-5	10.1	37
40	Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genetics*, **2008**, 4, e1000054	6	280
39	Functional assays for classification of BRCA2 variants of uncertain significance. *Cancer Research*, **2008**, 68, 3523-31	10.1	96
38	Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. *Cancer Informatics*, **2008**, 6, 203-16	2.4	40
37	Assessment of functional effects of unclassified genetic variants. *Human Mutation*, **2008**, 29, 1314-26	4.7	85
36	Prediction and assessment of splicing alterations: implications for clinical testing. *Human Mutation*, **2008**, 29, 1304-13	4.7	98
35	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. *International Journal of Cancer*, **2008**, 122, 2017-22	7.5	268
34	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
33	A common coding variant in CASP8 is associated with breast cancer risk. *Nature Genetics*, **2007**, 39, 352-8	36.3	557
32	Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*, **2007**, 447, 1087-93	36.4	1957
31	The prevalence of BRCA2 mutations in familial pancreatic cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 342-6	4	217
30	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 1416-21	4	26
29	Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. *Cancer Research*, **2007**, 67, 1494-501	10.1	98

28	Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancer. *Cancer Research*, **2007**, 67, 8412-8	10.1	62
27	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. *American Journal of Human Genetics*, **2007**, 81, 873-83	11	360
26	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
25	Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. *Breast Cancer Research*, **2007**, 9, R82	8.3	51
24	An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Research*, **2007**, 9, 104	8.3	121
23	Cancer risk assessment at the atomic level. *Cancer Research*, **2006**, 66, 1897-9	10.1	14
22	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. *JAMA - Journal of the American Medical Association*, **2006**, 296, 185-92	27.4	466
21	Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Molecular Cell*, **2006**, 22, 719-729	17.6	588
20	Targeted Therapy for BRCA2 Deficient Tumors. *Cancer Biology and Therapy*, **2005**, 4, 707-8	4.6	1
19	Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. *Oncogene*, **2005**, 24, 3652-6	9.2	61
18	Reply to Palacios et al., ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers *Genes Chromosomes and Cancer*, **2005**, 42, 206-206	5	
17	Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. *Cancer Research*, **2005**, 65, 383-6	10.1	85
16	Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. *Cancer Research*, **2005**, 65, 417-26	10.1	95
15	Genetic epidemiology of BRCA1. *Cancer Biology and Therapy*, **2004**, 3, 509-14	4.6	19
14	The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. *Journal of Mammary Gland Biology and Neoplasia*, **2004**, 9, 109-18	2.4	79
13	Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. *American Journal of Human Genetics*, **2004**, 75, 535-44	11	312
12	BRCA2 and pancreatic cancer. *International Journal of Gastrointestinal Cancer*, **2002**, 31, 99-106		36
11	Is BRCA1 associated with familial breast cancer in India?. *Cancer Biology and Therapy*, **2002**, 1, 22-3	4.6	1

10	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2002**, 94, 1773-9	9.7	266
9	TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. *Cancer Research*, **2002**, 62, 3587-91	10.1	61
8	Genetic heterogeneity in Peutz-Jeghers syndrome. *Human Mutation*, **2000**, 16, 23-30	4.7	109
7	p73 mutations are not detected in sporadic and hereditary breast cancer. *Breast Cancer Research and Treatment*, **1999**, 58, 25-9	4.4	13
6	I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer **1999**, 85, 189-190		5
5	BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. *New England Journal of Medicine*, **1997**, 336, 1409-15	59.2	587
4	Localization of the human homolog of the yeast cell division control 27 gene (CDC27) proximal to ITGB3 on human chromosome 17q21.3. *Somatic Cell and Molecular Genetics*, **1995**, 21, 351-5		1
3	Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. *Nature Genetics*, **1994**, 8, 387-91	36.3	350
2	Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework		1
1	Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing		1